Board Member
Tvardi Therapeutics, Inc. (TVRD)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Imran Alibhai is recorded as CEO and Board Member at Tvardi Therapeutics, Inc. (TVRD). Tvardi Therapeutics, Inc. reported in an 8-K filed April 15, 2025 that Imran Alibhai was appointed Chief Executive Officer, effective April 15, 2025. Tvardi Therapeutics, Inc. reported in an 8-K filed April 15, 2025 that Imran Alibhai was appointed Class II director, effective April 15, 2025. Imran Alibhai has spoken on 1 investor event across 1 company, most recently for Tvardi Therapeutics, Inc. on June 4, 2026.
“Imran Alibhai, Ph.D., was appointed as the Company's Chief Executive Officer and a member of our board of directors upon the closing of the Merger.”
“In accordance with the Merger Agreement, effective upon at the closing of the Merger on April 15, 2025, the board of directors and its committees were reconstituted, with Susan Shiff, Ph.D. and Michael Wyzga appointed as Class I directors, whose terms expire at the Company's 2027 annual meeting, Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah appointed as Class II directors, whose terms expire at the Company's 2025 annual meeting, and Wallace Hall and Shaheen Wirk, M.D. appointed as Class III directors, whose terms expire at the Company's 2026 annual meeting.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2025-04-15–present
2025-04-15–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2025-04-15–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
